NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
Key patent now granted in major markets including the U.S., Europe, Canada & South Korea
Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) &...
NLS Pharmaceutics Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex® (Mazindol)
Agreement provides exclusive rights to all available data included in the original new drug application ("NDA") for mazindol in the U.S.
$NLSP announces that it has entered into a License Agreement (the "Agreement") with Novartis Pharma AG, whereby...
NLS Pharmaceutics (NASDAQ:NLSP) announces that it has entered into a License Agreement with Novartis Pharma AG, for all of the available data in the original NDA for Sanorex (mazindol) submitted to the U.S. FDA in February 1972
Share your opinion in the comments and support the idea with likes.
Thank you for your support!
